162 related articles for article (PubMed ID: 25872531)
1. The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial.
Low JG; Wijaya L; Li GK; Lim EY; Shum AK; Cheung YB; Ooi EE
Trials; 2015 Apr; 16():147. PubMed ID: 25872531
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
4. Differential dengue cross-reactive and neutralizing antibody responses in BALB/c and Swiss albino mice induced by immunization with flaviviral vaccines and by infection with homotypic dengue-2 virus strains.
Lim CS; Chua JJ; Wilkerson J; Chow VT
Viral Immunol; 2006; 19(1):33-41. PubMed ID: 16553548
[TBL] [Abstract][Full Text] [Related]
5. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y
Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677
[TBL] [Abstract][Full Text] [Related]
6. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
[TBL] [Abstract][Full Text] [Related]
8. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine.
Eckels KH; Kliks SC; Dubois DR; Wahl LM; Bancroft WH
J Immunol; 1985 Dec; 135(6):4201-3. PubMed ID: 4067313
[TBL] [Abstract][Full Text] [Related]
9. An experimental medicine decipher of a minimum correlate of cellular immunity: Study protocol for a double-blind randomized controlled trial.
Kalimuddin S; Chan YFZ; Sessions OM; Chan KR; Ong EZ; Low JG; Bertoletti A; Ooi EE
Front Immunol; 2023; 14():1135979. PubMed ID: 36969244
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.
López P; Lanata CF; Zambrano B; Cortés M; Andrade T; Amemiya I; Terrones C; Gil AI; Verastegui H; Marquez V; Crevat D; Jezorwski J; Noriega F
Pediatr Infect Dis J; 2016 Oct; 35(10):1140-7. PubMed ID: 27254034
[TBL] [Abstract][Full Text] [Related]
11. Changes in dengue and Japanese encephalitis (JE) antibody after JE vaccination.
Quina MA; Thein S; Auvanich W; Okuno Y; Igarashi A; Fukai K
Biken J; 1978 Dec; 21(4):149-59. PubMed ID: 754688
[TBL] [Abstract][Full Text] [Related]
12. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
[TBL] [Abstract][Full Text] [Related]
13. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
Monath TP; Craven RB; Muth DJ; Trautt CJ; Calisher CH; Fitzgerald SA
Am J Trop Med Hyg; 1980 Jul; 29(4):624-34. PubMed ID: 7406113
[TBL] [Abstract][Full Text] [Related]
14. Single-Cell Analysis of B Cell/Antibody Cross-Reactivity Using a Novel Multicolor FluoroSpot Assay.
Hadjilaou A; Green AM; Coloma J; Harris E
J Immunol; 2015 Oct; 195(7):3490-6. PubMed ID: 26320246
[TBL] [Abstract][Full Text] [Related]
15. Studies on serological cross-reaction in sequential flavivirus infections.
Makino Y; Tadano M; Saito M; Maneekarn N; Sittisombut N; Sirisanthana V; Poneprasert B; Fukunaga T
Microbiol Immunol; 1994; 38(12):951-5. PubMed ID: 7723688
[TBL] [Abstract][Full Text] [Related]
16. Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection.
Santos-Peral A; Luppa F; Goresch S; Nikolova E; Zaucha M; Lehmann L; Dahlstroem F; Karimzadeh H; Thorn-Seshold J; Winheim E; Schuster EM; Dobler G; Hoelscher M; Kümmerer BM; Endres S; Schober K; Krug AB; Pritsch M; Barba-Spaeth G; Rothenfusser S
Nat Commun; 2024 Feb; 15(1):1696. PubMed ID: 38402207
[TBL] [Abstract][Full Text] [Related]
17. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
[TBL] [Abstract][Full Text] [Related]
18. Immune correlates for dengue vaccine development.
Srikiatkhachorn A; Yoon IK
Expert Rev Vaccines; 2016; 15(4):455-65. PubMed ID: 26560015
[TBL] [Abstract][Full Text] [Related]
19. Novel vaccination approach for dengue infection based on recombinant immune complex universal platform.
Kim MY; Reljic R; Kilbourne J; Ceballos-Olvera I; Yang MS; Reyes-del Valle J; Mason HS
Vaccine; 2015 Apr; 33(15):1830-8. PubMed ID: 25728317
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.
Chan KR; Wang X; Saron WAA; Gan ES; Tan HC; Mok DZL; Zhang SL; Lee YH; Liang C; Wijaya L; Ghosh S; Cheung YB; Tannenbaum SR; Abraham SN; St John AL; Low JGH; Ooi EE
Nat Microbiol; 2016 Sep; 1(12):16164. PubMed ID: 27642668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
